About this project
Atrial fibrillation (AF) is a common condition, yet few people have heard of it. What is often not known is that AF is the second most important risk factor for stroke, after blood pressure. Some 1 in 5 strokes is due to AF – close to 360,000 cases per year in the EU – and AF-related strokes are the most fatal and costly of strokes.
The good news is that effective therapies are available that help reduce the risk of stroke in people with AF. But many patients at significant risk of stroke – up to 40% in many countries – are not offered these treatments, despite a strong evidence base and consistent international guidelines recommending their use.
The challenge, as ever, is one of implementation. But successful implementation requires up-to-date, reliable data to help understand what are the most important unmet needs in each country, and where efforts should be targeted to achieve the greatest returns.